STOCK TITAN
  1. Home
  2. News
  3. LGVN

Longeveron Inc - LGVN STOCK NEWS

IMPACT
SENTIMENT
LGVN : Nasdaq LGVNR : Nasdaq
Longeveron Announces Closing of $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
offering
IMPACT
SENTIMENT
LGVN : Nasdaq LGVNR : Nasdaq
Longeveron Announces $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
offering
IMPACT
SENTIMENT
LGVN : Nasdaq LGVNR : Nasdaq
Longeveron Announces Positive Top-Line Results for Lomecel-B™ in its CLEAR MIND Phase 2a Clinical Trial in the Treatment of Mild Alzheimer’s Disease
clinical trial
IMPACT
SENTIMENT
LGVN : Nasdaq LGVNR : Nasdaq
Longeveron Issues Letter to Stockholders
IMPACT
SENTIMENT
LGVN : Nasdaq LGVNR : Nasdaq
Long-term Survival Data from Longeveron’s ELPIS 1 Trial Accepted for Presentation at the 2023 Scientific Sessions of the American Heart Association
IMPACT
SENTIMENT
LGVN : Nasdaq LGVNR : Nasdaq
Longeveron to Present at the 25th Annual H.C. Wainwright Global Investment Conference
conferences
IMPACT
SENTIMENT
LGVN : Nasdaq LGVNR : Nasdaq
Longeveron to Participate in the 149th Annual National Investment Banking Association Conference
conferences
IMPACT
SENTIMENT
LGVN : Nasdaq
Longeveron Rights Offering Subscription Period Begins
IMPACT
SENTIMENT
LGVN : Nasdaq
Longeveron Rights Offering Declared Effective and Calendar Finalized
IMPACT
SENTIMENT
LGVN : Nasdaq
Longeveron to Host Key Opinion Leader Event on Medicinal Signaling Cells (MSCs) for Hypoplastic Left Heart Syndrome (HLHS) with Lomecel-B™ on August 16, 2023
conferences
Stock LGVN logo
Longeveron Inc
Nasdaq:LGVN

LGVN Stock Data

Pharmaceutical Preparation Manufacturing
Manufacturing
Link

About LGVN

longeveron llc is a leading global regenerative medicine company developing innovative cellular therapeutics for chronic life-threatening diseases. our lead investigational product candidate (lmsc) is based on a specialized cell known as a mesenchymal stem cell that is derived from the bone marrow of healthy young adult donors. our allogeneic, ‘off-the-shelf’ product is under investigation for chronic conditions of the elderly, and other life- threatening diseases, for which no approved therapeutics currently exist: • aging frailty syndrome • alzheimer’s disease • hypoplastic left heart syndrome • the metabolic syndrome